ReViral picks up $55 mln Series B
UK-based ReViral, an antiviral drug discovery and development company, has closed $55 million in Series B financing. New Leaf Venture Partners and Novo Ventures led the round with participation from Perceptive Advisors, Andera Partners, OrbiMed and Brace Pharma Capital. In conjunction with the financing, representatives of New Leaf Ventures and Novo Ventures will join the ReViral board of directors.
1 August 2018•1 min read
